19.07.2011 • News

Avery Dennison Details Weak Q2 Outlook

Avery Dennison provided a weak second-quarter outlook and also cut its expectations for the full year. The company attributed the weak outlook to a nearly 5% decline in unit volumes at its Pressure-sensitive Materials, and Retail Branding & Information Solutions segments.

For the second quarter, the company expects earnings of $0.64 to $0.69 per share, and adjusted earnings of $0.74 to $0.79 per share.

On average, seven analysts polled by Thomson Reuters expect earnings of $0.88 per share for the quarter. Analysts' estimates typically exclude special items.

The Pasadena, California-based company expects second-quarter revenues of about $1.7 billion. Wall Street analysts expected revenues of $1.83 billion for the quarter.

CEO Dean Scarborough said, "In the second quarter, volume in our two largest segments was negatively impacted as consumer packaged goods companies and apparel retailers and brands became more cautious about consumer sentiment and the impact of rising retail prices to offset inflation.

For the full year 2011, Avery Dennison expects earnings in the range of $2.25 to $2.55 per share. The company further cut its full-year adjusted earnings outlook, and now expects it in the range of $2.45 to $2.75 per share, compared with its prior outlook of $3.00 to $3.30 per share. The company expects revenues of $6.8 to $6.9 billion.

Street analysts currently expect the company to earn $3.04 per share on revenues of $7.06 billion for the full year.

 

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read